Miglustat

證據等級: L5

預測適應症: 10 個

Miglustat: From Gaucher Disease to Tay-Sachs Disease (GM2 Gangliosidosis)

One-Sentence Summary

Miglustat is a glucosylceramide synthase inhibitor (substrate reduction therapy) originally approved in the EU for type 1 Gaucher disease. Among the ten indications predicted by TxGNN, Tay-Sachs disease (GM2 gangliosidosis) is the only candidate backed by real-world data — 5 clinical trials (including a completed randomized controlled study) and 20 publications — even though it ranks lower on the raw TxGNN score than several mechanistically weaker, evidence-free candidates.

Note on candidate selection: TxGNN's #1-ranked prediction ("autosomal ichthyosis syndrome with fatal disease course") has zero supporting trials or literature and, per the model's own rationale note, a "weak mechanistic link." Tay-Sachs disease (rank 7 by score) is the only prediction in this pack with substantive clinical evidence, so this report focuses on it as the actionable candidate.

Quick Overview

Item	Content
Original Indication	Gaucher disease type 1 (per literature evidence in this pack; official regulatory indication text unavailable — see Data Gaps)
Predicted New Indication	Tay-Sachs disease (GM2 gangliosidosis)
TxGNN Prediction Score	99.75% (rank 3492 of full candidate set)
Evidence Level	L2 (1 completed randomized controlled trial + supporting systematic review)
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed DrugBank MOA data is marked as a data gap in this pack, but the mechanism is well documented in the literature evidence collected: miglustat is an orally administered glucosylceramide glucosyltransferase (glucosylceramide synthase) inhibitor, working as a substrate reduction therapy (SRT) for glycosphingolipid (GSL) storage disorders (PMID 12808890, 11227045, 16763917).

Tay-Sachs disease is caused by β-hexosaminidase A deficiency, leading to lysosomal accumulation of GM2 ganglioside — a glycosphingolipid synthesized via the same upstream glucosylceramide pathway that miglustat inhibits. Because miglustat reduces the production of GSL substrates (including GM2 ganglioside precursors) rather than replacing the missing enzyme, the mechanistic rationale for extending it from Gaucher disease (glucosylceramide accumulation) to Tay-Sachs disease (GM2 ganglioside accumulation) is direct and biologically plausible — unlike most of the other TxGNN-predicted candidates in this pack, whose target diseases involve unrelated storage pathways (cholesterol esters, sulfatides, steroid sulfate).

This mechanistic plausibility is also reflected in the trial record: miglustat has already been studied in animal models and human patients with Tay-Sachs/Sandhoff (GM2 gangliosidosis) disease since the late 1990s, culminating in an RCT and a 2023 systematic review — making this the most mature repurposing candidate in the pack, notwithstanding mixed efficacy results (see below).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00672022	Phase 3	Completed	10	PK, safety and tolerability of miglustat in infantile-onset GM2 gangliosidosis (single/steady-state oral dosing)
NCT00418847	Phase 2	Completed	5	PK and tolerability of miglustat in juvenile GM2 gangliosidosis, single and multiple oral doses
NCT03822013	Phase 3	Terminated	30	Survey of miglustat's therapeutic effect on neurological/systemic symptoms in infantile Sandhoff and Tay-Sachs disease
NCT02030015	Phase 4	Terminated	16	Miglustat + ketogenic diet combination therapy for infantile/juvenile gangliosidoses (Syner-G study)
NCT07399704	Phase 2	Recruiting	21	Long-term safety/efficacy of nizubaglustat in GM2 gangliosidosis/NPC patients, including those previously on miglustat

Note: Two trials (NCT03822013, NCT02030015) were terminated, and the two completed Phase 2/3 studies were PK/tolerability studies rather than efficacy-driven RCTs — this tempers the strength of the clinical trial evidence despite the number of studies.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19346952	2009	RCT	Genet Med	12-month randomized controlled study (+24-month extension) evaluating miglustat safety/efficacy in late-onset Tay-Sachs disease
37209042	2023	Systematic Review	Eur J Neurol	Systematic review finds prior studies on miglustat efficacy/safety in GM2 gangliosidosis are inconsistent
32867370	2020	Review	Int J Mol Sci	Overview of GM2 gangliosidosis clinical features, pathophysiology, and current therapies including SRT
30743792	2009	Review	Expert Rev Endocrinol Metab	Substrate reduction therapy with miglustat for glycosphingolipid storage disorders affecting the brain
12808890	2003	Review (Drug Profile)	Curr Opin Investig Drugs	Confirms EU approval of miglustat for Gaucher disease and its development for Tay-Sachs, Fabry, and NPC diseases
30524313	2018	Review	Front Physiol	Reviews new therapeutic approaches to Tay-Sachs disease, including substrate reduction therapy
11227045	2001	Review	Expert Opin Investig Drugs	Early review of substrate reduction therapy rationale for glycosphingolipid storage disorders
18618288	2008	Pilot Study	J Inherit Metab Dis	Neurocognitive testing pilot study in late-onset Tay-Sachs disease as a candidate outcome measure
16434676	2006	Case Report	Neurology	SRT with miglustat in 2 infantile Tay-Sachs patients: did not arrest neurologic deterioration, though CSF drug levels and macrocephaly prevention were observed
28476546	2017	Observational	Mol Genet Metab	Natural history mapping of infantile gangliosidosis; notes miglustat use limited by GI side effects

Germany Market Information

Miglustat is currently not marketed in this jurisdiction (market_status: 未上市) and no authorization records are present in this Evidence Pack (total_licenses: 0). No product/authorization table can be generated.

Safety Considerations

Please refer to the package insert for safety information.

⚠️ Critical Data Gap: Detailed TFDA package insert warnings and contraindications (DG001) are marked as a Blocking gap in this Evidence Pack, meaning this candidate cannot yet proceed to S1 safety pre-assessment. Known real-world safety issues with miglustat (from its approved use in Gaucher/NPC) include gastrointestinal side effects (diarrhea, weight loss) and peripheral neuropathy, but these are not sourced from this pack's structured safety fields and should be independently verified before clinical use.

Conclusion and Next Steps

Decision: Hold

Rationale: Although miglustat has a mechanistically sound rationale and an unusually rich trial/literature record compared to other candidates in this pack, the evidence is mixed — two trials were terminated, the only RCT and the 2023 systematic review report inconsistent efficacy, and a completed case series found no arrest of neurologic decline in infantile Tay-Sachs disease. Combined with a Blocking data gap on TFDA safety labeling, the candidate is not yet ready to advance.

To proceed, the following is needed:

Resolve DG001: obtain TFDA/official package insert warnings and contraindications
Resolve DG002: obtain confirmed DrugBank MOA record (currently inferred only from literature)
Independent efficacy assessment reconciling the 2023 systematic review's "inconsistent" findings with the 2009 RCT's positive extension data
Root-cause review of why NCT03822013 and NCT02030015 were terminated (safety vs. enrollment vs. futility)
Regulatory pathway assessment given the drug is not currently marketed in this jurisdiction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.